Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610971 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2499199 | 0.90 | NPC1 (0.56) | ALDH1A1LMNAKMT2AMTNR1AMTNR1B | |
| SCHEMBL6280282 | 0.88 | MTNR1A (0.51) | ALDH1A1KMT2AMTNR1AMTNR1BMAPT | |
| SCHEMBL11599893 | 0.87 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2AMTNR1AMTNR1B | |
| SCHEMBL29766169 | 0.86 | NPC1 (0.52) | ALDH1A1LMNAKMT2AMTNR1AMTNR1B | |
| SCHEMBL5043303 | 0.86 | NPC1 (0.52) | ALDH1A1LMNAKMT2AMTNR1AMTNR1B | |
| SCHEMBL8597033 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNAL3MBTL1MTNR1AMTNR1B | |
| SCHEMBL9787091 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3193858 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7455676 | 0.82 | NPC1 (0.50) | ALDH1A1LMNAKMT2AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | The Board of Directors of the University of Illinois (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | The Board of Directors of the University of Illinois (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3573977-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLNOIS (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLNOIS (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-7449483-B2 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | AEBI JOHANNES | 2007-05-03 | — | — | US | disclosed |
| US-7173043-B2 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | AEBI JOHANNES | 2005-12-01 | — | — | US | disclosed |
| US-6951879-B2 | Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1334094-B1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1334094-A1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. | 2002-07-04 | — | — | US | disclosed |
| WO-2002036584-A1 | CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ALDH1A1 2935/4885CYP1A2 3656/4885CYP3A4 4408/4885 |
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | ESR1, ESR2, GPER1 | ALDH1A1 1567/4885CYP1A2 201/4885CYP3A4 381/4885 |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | LSS, CYP51A1, CYP46A1 | ALDH1A1 2721/4885CYP1A2 235/4885CYP3A4 624/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ALDH1A1 2935/4885CYP1A2 3656/4885CYP3A4 4408/4885 |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | ALDH1A1 3430/4885CYP1A2 169/4885CYP3A4 321/4885 |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | ALDH1A1 3430/4885CYP1A2 169/4885CYP3A4 321/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ALDH1A1 2935/4885CYP1A2 3656/4885CYP3A4 4408/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ALDH1A1 2935/4885CYP1A2 3656/4885CYP3A4 4408/4885 |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ALDH1A1 2935/4885CYP1A2 3656/4885CYP3A4 4408/4885 |
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | ESR1, ESR2, GPER1 | ALDH1A1 1567/4885CYP1A2 201/4885CYP3A4 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.